Damora Therapeutics announced new preclinical data for DMR-001, a therapy targeting mutant calreticulin (mutCALR) in myeloproliferative neoplasms (MPN), showing strong activity against various CALR mutations. Presented at the 2026 ASH Annual Meeting, the data highlight DMR-001's potential as a best-in-class treatment for essential thrombocythemia and myelofibrosis driven by mutCALR. The ongoing CLARITY-101 Phase 1/1b trial is testing DMR-001's safety and dosage, aiming to advance clinical development rapidly. This therapy could address a significant unmet need as current treatments do not target the underlying cause of these blood disorders.
Damora Therapeutics' new preclinical data on DMR-001 provides context for readers following health sector innovations. For readers following health sector stocks, here is Pluang's market snapshot as of Nov 04, 2026 20:41 WIB: out of 150 priced US health stocks, 127 rose and 19 fell. Notable movers include CGC at USD 0.75 with a 5.70% increase and 100% buy order activity, NVO at USD 42.40 up 5.50%, and AMGN at USD 486.50 with a 5.47% gain.
The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...
Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...
The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...
Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...
Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...
